2005 Annual Meeting | Using AAN Guidelines and Best Current Evidence in Daily Practice

Date Saturday 04/09/05

Time 02:15 PM - 06:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type PM Half-Day Course

Director(s) Gary S. Gronseth, MD, FAAN

Topic(s) Practice Management

Learning Objectives Upon completion:
Participants should be able to assess whether any published study provides strong or weak evidence; understand the ways in which methodological quality is assessed for therapeutic, diagnostic, and prognostic studies; understand the diagnostic/prognostic value of transcranial doppler in neurovascular conditions; determine which modalities are effective in treating essential tremor; and understand the prognostic and treatment implications of the presence of a patent foramen ovale in patients with cryptogenic stroke.

CME Available No CME available

Program Level Advanced

Recommended Audience Practitioner, Fellow, Academician, Resident

Event Timeline
02:15 PM - 03:10 PM		Translating Best Evidence into Best Practice Gary S. Gronseth, MD, FAAN
03:10 PM - 04:00 PM		Treating Essential Tremor Theresa A. Zesiewicz, MD
04:00 PM - 04:20 PM		Break
04:20 PM - 05:10 PM		The Usefulness of Transcranial Doppler Michael A. Sloan, MD, MS, FAAN
05:10 PM - 06:00 PM		Prognostic and Treatment Implications of a Patent Foramen Ovale Steven R. Messe, MD, FAHA, FAAN

Faculty Disclosures
Gary S. Gronseth, MD, FAAN	Dr. Gronseth has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Brain & Life. Dr. Gronseth has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology. Dr. Gronseth has received personal compensation in the range of $0-$499 for serving as a Member/EBM consultant Guideline Development Subcommittee with AAN.
Michael A. Sloan, MD, MS, FAAN	No disclosure on file
Steven R. Messe, MD, FAHA, FAAN	Dr. Messe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. Dr. Messe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Terumo. Dr. Messe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for WL Gore. The institution of Dr. Messe has received research support from WL Gore. The institution of Dr. Messe has received research support from Mallinkrodt. The institution of Dr. Messe has received research support from Biogen. Dr. Messe has received intellectual property interests from a discovery or technology relating to health care. Dr. Messe has received publishing royalties from a publication relating to health care. Dr. Messe has received personal compensation in the range of $500-$4,999 for serving as a Clinical Event Committee for the CONFORMAL left atrial appendage occlusion trial with Yale Cardiovascular Research Group.
Theresa A. Zesiewicz, MD	Dr. Zesiewicz has received personal compensation for serving as an employee of Medscape. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care.